Sprouty-Related, EVH1 Domain Containing 1 (SPRED1) (N-Term) Peptide
| Name | Sprouty-Related, EVH1 Domain Containing 1 (SPRED1) |
| Synonyms | AL024345, AW047647, 5730461F13Rik, NFLS, FLJ33903, fb14c08, fj51c03, zgc:85707, wu:fb14c08, wu:fj51c03, Xspred1, MGC79569, Xtspred1 |
| Binding Site |
N-Term |
 |
2 references available |
| Certificates | ISO 9001:2008 |
| Catalog no. | ABIN692440 |
| Quantity | 0.1 mg |
| Price | 49.50 $ Plus shipping costs $45.00 |
| Shipping to |
|
| Availability | Will be delivered in 2 to 3 Business Days |
Additional Information
| Immunogen | Synthetic peptide |
| Characteristics | Blocking peptide for SPRED1 (N-term) antibody ABIN388231 |
| Specificity | The synthetic peptide sequence used to generate the antibody AP1449d was selected from the N-term region of human SPRED1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
| Comments |
Background: SPRED1 is a tyrosine kinase substrate that inhibits growth-factor-mediated activation of MAP kinase. |
Application Details
| Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles |
| Restrictions | For Research Use only |
Publications
| Product |
Yoshida, Hisamoto, Akiba et al.: "Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors." in: Oncogene, Vol. 25, Issue 45, pp. 6056-66, 2006 (PubMed).
Brems, Chmara, Sahbatou et al.: "Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype." in: Nature genetics, Vol. 39, Issue 9, pp. 1120-6, 2007 (PubMed). |
